Diuresis with associated glucose and sodium excretion might help explain the “highly impressive and unexpected” reductions in heart failure hospitalisation, all-cause death and cardiovascular death in the EMPA-REG Outcomes study of empagliflozin, a recent review has suggested. As one of a large number of FDA-mandated studies to establish the cardiovascular safety of newer treatments for ...
Type 2 diabetes
Why were the results of EMPA-REG so surprising?
13 Jul 2016